| Period | JFNCX Return | Category Return Low | Category Return High | Rank in Category (%) | Quintile |
|---|---|---|---|---|---|
| YTD | 13.0% | -14.9% | 27.0% | 35.71% | 2 |
| 1 Yr | 10.5% | -14.8% | 49.6% | 49.55% | 3 |
| 3 Yr | 1.5% * | -7.5% | 17.2% | 67.59% | 4 |
| 5 Yr | 16.0% * | 7.0% | 23.4% | 34.58% | 2 |
| 10 Yr | 13.0% * | 6.1% | 19.3% | 47.57% | 3 |
* Annualized
| Period | JFNCX Return | Category Return Low | Category Return High | Rank in Category (%) | Quintile |
|---|---|---|---|---|---|
| 2017 | 20.3% | -19.5% | 43.9% | 41.82% | 3 |
| 2016 | -14.1% | -29.8% | 14.5% | 50.00% | 3 |
| 2015 | -2.0% | -20.4% | 33.7% | 49.09% | 3 |
| 2014 | 20.4% | -5.8% | 48.1% | 29.09% | 2 |
| 2013 | 42.0% | -3.1% | 65.2% | 42.20% | 3 |
| Period | JFNCX Return | Category Return Low | Category Return High | Rank in Category (%) | Quintile |
|---|---|---|---|---|---|
| YTD | 13.0% | -14.9% | 27.0% | 36.04% | 2 |
| 1 Yr | 9.5% | -18.3% | 49.6% | 46.36% | 3 |
| 3 Yr | 1.5% * | -14.2% | 16.9% | 60.19% | 3 |
| 5 Yr | 16.0% * | 6.3% | 23.4% | 30.84% | 2 |
| 10 Yr | 13.0% * | 6.1% | 19.3% | 46.60% | 3 |
* Annualized
| Period | JFNCX Return | Category Return Low | Category Return High | Rank in Category (%) | Quintile |
|---|---|---|---|---|---|
| 2017 | 20.3% | -19.5% | 43.9% | 42.20% | 3 |
| 2016 | -14.1% | -25.1% | 39.1% | 52.29% | 3 |
| 2015 | 8.0% | -16.6% | 100.0% | 48.62% | 3 |
| 2014 | 44.2% | -5.8% | 79.8% | 17.43% | 1 |
| 2013 | 100.1% | 0.0% | 398.7% | 20.37% | 1 |
| JFNCX | Category Low | Category High | JFNCX % Rank | Quintile | |
|---|---|---|---|---|---|
| Net Assets | 3.72 B | 16.3 M | 45.3 B | 8.93% | 2 |
| Number of Holdings | 99 | 30 | 380 | 12.50% | 2 |
| Net Assets in Top 10 | 882 M | 8.3 M | 18.4 B | 12.50% | 2 |
| Weighting of Top 10 | 24.7% | 20.4% | 73.1% | 36.61% | 5 |
| Weighting | Category Low | Category High | JFNCX % Rank | Quintile | |
|---|---|---|---|---|---|
| Stocks | 95.38% | 91.25% | 99.78% | 33.04% | 5 |
| Other | 2.53% | -1.15% | 5.64% | 1.79% | 1 |
| Cash | 1.62% | 0.00% | 7.04% | 16.07% | 3 |
| Convertible Bonds | 0.47% | 0.00% | 0.47% | 0.89% | 1 |
| Preferred Stocks | 0.00% | 0.00% | 2.32% | 10.71% | 3 |
| Bonds | 0.00% | 0.00% | 4.69% | 3.57% | 3 |
| Weighting | Category Low | Category High | JFNCX % Rank | Quintile | |
|---|---|---|---|---|---|
| Healthcare | 91.82% | 9.78% | 99.78% | 33.04% | 5 |
| Technology | 3.56% | 0.00% | 69.25% | 5.36% | 1 |
| Utilities | 0.00% | 0.00% | 0.48% | 1.79% | 3 |
| Real Estate | 0.00% | 0.00% | 1.07% | 2.68% | 3 |
| Industrials | 0.00% | 0.00% | 8.36% | 9.82% | 4 |
| Financial Services | 0.00% | 0.00% | 5.45% | 6.25% | 3 |
| Energy | 0.00% | 0.00% | 0.10% | 1.79% | 3 |
| Communication Services | 0.00% | 0.00% | 0.00% | 0.89% | 3 |
| Consumer Defense | 0.00% | 0.00% | 1.31% | 10.71% | 4 |
| Consumer Cyclical | 0.00% | 0.00% | 7.68% | 8.93% | 4 |
| Basic Materials | 0.00% | 0.00% | 0.58% | 2.68% | 3 |
| Weighting | Category Low | Category High | JFNCX % Rank | Quintile | |
|---|---|---|---|---|---|
| US | 78.18% | 63.89% | 99.64% | 30.36% | 4 |
| Non US | 17.20% | 0.00% | 35.89% | 8.04% | 2 |
| JFNCX Fees (% of AUM) | Category Low | Category High | Rank in Category (%) | Quintile | |
|---|---|---|---|---|---|
| Expense Ratio | 1.76% | 0.10% | 4.31% | 23.21% | 4 |
| Management Fee | 0.64% | 0.09% | 1.25% | 11.61% | 2 |
| 12b-1 Fee | 1.00% | 0.00% | 1.00% | 1.27% | 4 |
| Administrative Fee | N/A | 0.01% | 0.40% | N/A | N/A |
| JFNCX Fees (% of AUM) | Category Low | Category High | JFNCX Rank | Quintile | |
|---|---|---|---|---|---|
| Front Load | N/A | 2.50% | 5.75% | N/A | N/A |
| Deferred Load | 1.00% | 1.00% | 5.00% | 12.12% | 2 |
| JFNCX Fees (% of AUM) | Category Low | Category High | JFNCX Rank | Quintile | |
|---|---|---|---|---|---|
| Max Redemption Fee | N/A | 0.75% | 2.00% | N/A | N/A |
Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.
| JFNCX Fees (% of AUM) | Category Low | Category High | JFNCX Rank | Quintile | |
|---|---|---|---|---|---|
| Turnover | 38.00% | 0.00% | 699.00% | 16.96% | 4 |
| JFNCX | Category Low | Category High | JFNCX % Rank | Quintile | |
|---|---|---|---|---|---|
| Dividend Yield | N/A | 0.01% | 0.94% | N/A | N/A |
| JFNCX | Category Low | Category High | Category Mode | |
|---|---|---|---|---|
| Dividend Distribution Frequency | Annually | Annually | Quarterly | Annually |
| JFNCX | Category Low | Category High | JFNCX % Rank | Quintile | |
|---|---|---|---|---|---|
| Net Income Ratio | -0.59% | -2.22% | 1.46% | 43.75% | 3 |
| JFNCX | Category Low | Category High | Capital Mode | |
|---|---|---|---|---|
| Capital Gain Distribution Frequency | Annually | Annually | Semi-Annually | Annually |
Manager
Start Date
May 01, 2007Tenure
11.17
Tenure Rank
10.2%
Andy Acker is a Portfolio Manager on the Janus Global Life Sciences strategy, a position he has held since 2007. He also serves as co-team leader of the health care sector research team and as a Research Analyst covering the biotechnology sector. Mr. Acker served as assistant portfolio manager on the Global Life Sciences strategy from 2003 to 2007 and as co-portfolio manager of the Janus Aspen Global Life Sciences Portfolio from 2004 to 2007. Mr. Acker joined Janus in 1999 as a research analyst, focusing on companies in the biotechnology and pharmaceutical industries. Prior to Janus, he worked as a strategy consultant for the Boston Consulting Group and as a health care analyst for Morgan Stanley Venture Partners. Mr. Acker received his bachelor of science degree in biochemical sciences from Harvard University, graduating magna cum laude and Phi Beta Kappa. He also earned an MBA from Harvard Business School, graduating with honors. Mr. Acker holds the Chartered Financial Analyst designation.
Manager
Start Date
Jan 12, 2016Tenure
2.47
Tenure Rank
20.9%
Ethan Lovell is a Portfolio Manager responsible for co-managing the Janus Global Life Sciences strategy, a position he has held since 2016. Prior to this, Mr. Lovell served as assistant portfolio manager on the strategy. He is also a Research Analyst, primarily focusing on the global pharmaceutical and medical device industries and serves as a co-team leader of the health care sector research team. Prior to joining Janus as a research analyst in 2007, Mr. Lovell was a director at ClearBridge Advisors covering companies in the pharmaceutical, biotechnology and medical device industries. Previously, he was managing director and founding partner of Saranac Capital, LP, where he was the health care sector portfolio manager. Mr. Lovell also worked at Salomon Brothers Asset Management as a director, then managing director of the health care team. He began his career at Bear, Stearns & Co. as an equity research analyst covering biotechnology, pharmaceuticals and life science tool companies. He received his bachelor of arts from Bowdoin College with a double major in chemistry and economics and his MBA from Tulane University.
Category Low
0.1
Category High
20.8
Category Average
9.46
Category Mode
3.5
MutualFunds.com provides weekly information about any material impact on the mutual funds...
MutualFunds.com provides weekly information about any material impact on the mutual funds...
MutualFunds.com provides weekly information about any material impact on the mutual funds...
Creating a properly diversified portfolio can be a difficult proposition, especially when...
Low Volatility ETFs invest in securities with low volatility characteristics. These funds tend to have relatively stable share prices, and higher than average yields.
Investors who suspect that the stock market may be about to decline can take action to reduce the...